BPC-157: what the published literature actually describes

A pentadecapeptide that appears in a great many pre-clinical papers and very few clinical ones. Here is what is characterised, what is still hypothesis, and how to read a lot certificate before you buy anything.

Reviewed 30 July 2026 · For laboratory research use only

BPC-157 is a synthetic 15-amino-acid peptide whose sequence corresponds to a fragment of a protein found in human gastric juice. It has accumulated an unusual literature: a large pre-clinical body describing effects on signalling pathways in animal and cell models, and a very small clinical one. Those two things are frequently conflated when the compound is discussed, so this piece keeps them apart.

Molecular identity

The compound is well characterised analytically, which matters because it is the part a buyer can actually verify against a supplier's paperwork.

Pathways described in the literature

Published pre-clinical work associates the peptide with three signalling systems: VEGFR2, the nitric oxide system, and the EGF receptor. A 2025 review in Pharmaceuticals surveys this material and discusses the proposed nitric-oxide, VEGF and growth-factor mechanisms across gastric, musculoskeletal, cardiovascular and central-nervous-system models.²

A separate 2025 systematic review in the HSS Journal examined orthopaedic research specifically, and reported consistent signals for modulation of tendon, ligament and bone-repair pathways in animal models.¹ The authors' own framing is the important part: pre-clinical evidence with limited clinical evidence alongside it. Anyone citing this literature as settled in humans is overreading it.

On the clinical side the published record is thin. A pilot study examined the safety of intravenous infusion in human subjects.³ A pilot safety study is a starting point, not a demonstration of effect, and it should not be read as one.

Handling and stability

Reported handling conditions for the lyophilised material are storage at −20°C, with reconstituted material held at 2–8°C and used within about thirty days. Freeze–thaw cycling should be avoided and the material protected from light. It is soluble in bacteriostatic water or sterile saline.

How to read a certificate of analysis

Purity claims are where this market is weakest, and a certificate is only worth what its method makes it worth. Four things to check.

Is it lot-specific? A COA should name the lot you are receiving. A generic document showing that the compound was once made to specification says nothing about your vial.

Which methods were run? HPLC establishes purity as a percentage of peptide content. Mass spectrometry establishes identity — that the molecule present is the one on the label, at the expected mass. Purity without identity is a weaker claim than it looks.

Who ran it? An independent laboratory is a materially stronger signal than an in-house result, because the incentives differ.

Does the mass match? The observed mass should agree with 1,419.5 g/mol for this sequence. A disagreement is worth an explanation before anything else on the page matters.

References

1. Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, Apostolakos JM. “Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.” HSS Journal, 2025. doi:10.1177/15563316251355551
2. Józwiak M, Bauer M, Kamysz W, Kleczkowska P. “Multifunctionality and Possible Medical Application of the BPC 157 Peptide.” Pharmaceuticals, 2025. doi:10.3390/ph18020185
3. Lee E, Walker C, Ayadi B. “Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study.”